Anti-malarial activity in a Chinese herbal supplement containing Inonotus obliquus and Panax notoginseng

Anti-malarial activity in a Chinese herbal supplement containing Inonotus obliquus and Panax notoginseng
复制标题

DOI:
10.1016/j.parint.2021.102532
复制
发表时间:
2022-04-01
影响因子:
1.9
通讯作者:
Furuya, Tetsuya
Furuya, Tetsuya
中科院分区:
医学3区
文献类型:
--
作者:
Endo, Takuro;Nakagomi, Yuki;Furuya, Tetsuya

文献摘要

被引文献

相似文献

恶性疟原虫是最致命的人类疟疾寄生虫,在全世界感染患者中引起严重疾病,在非洲地区尤为重要。虽然世卫组织推荐青蒿素联合疗法治疗恶性疟原虫-疟疾,但青蒿素耐药寄生虫的出现已成为一个严重问题,这突出表明必须持续努力获得抗疟疾的新型化疗药物。作为这些努力的一部分,使用恶性疟原虫3D 7菌株测定了来自传统中药(TCM)的39种草药提取物的抗疟疾活性。三种草药补充剂似乎比其他补充剂具有更高的特异性抗疟疾活性。其中一个(D3)通过反相(第一步)和正相(第二步)液相色谱的两个连续分级分离,其中一些级分比D3或先前级分的比活性更高。用第一次分级分离的组分进行细胞毒性试验,结果显示无明显细胞毒性。这些结果表明,D3中抗疟疾活性的主要化合物的结构测定可能有助于未来开发更有效的化学品。
Plasmodium falciparum, the most virulent human malaria parasite, causes serious diseases among the infected patients in the world and is particularly important in African regions. Although artemisinin combination therapy is recommended by the WHO for treatment of P. falciparum-malaria, the emergence of artemisinin-resistant parasites has become a serious issue which underscores the importance of sustained efforts to obtain novel chemotherapeutic agents against malaria. As a part of such efforts, thirty-nine herbal extracts from traditional Chinese medicine (TCM) were assayed for their anti-malarial activity using 3D7 strain of P. falciparum. Three herbal supplements appeared to possess higher specific anti-malarial activity than the others. One of them (D3) was separated by two sequential fractionations with reverse-phase (the first step) and normal-phase (the second step) liquid chromatography, in which some fractions resulted in higher specific activities than those of D3 or the previous fractions. Cell toxicity assay was performed with the fractions of the first fractionation and demonstrated no obvious cell toxicity. These results suggest that structure determination of the major compound for the anti-malarial activity in D3 may help the development of more potent chemicals in the future.